A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07116616 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 166
Last updated 2026-05-18
Summary
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Conditions
Interventions
- DRUG
-
mRNA-2808
intravenous
Sponsors & Collaborators
-
ModernaTX, Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-30
- Primary Completion
- 2030-06-17
- Completion
- 2032-06-17
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
NCT02168101 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
NCT00530816 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
NCT00932698 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
NCT05336383 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
NCT03525678 ·Status: COMPLETED ·Phase: PHASE2
-
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
NCT01301807 ·Status: COMPLETED ·Phase: PHASE1
-
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT05913804 ·Status: RECRUITING ·Phase: PHASE1
-
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
NCT05052970 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
NCT04155749 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
NCT06232096 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
NCT01668719 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
NCT01160484 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
NCT02998047 ·Status: TERMINATED ·Phase: PHASE1
-
SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma
NCT00006013 ·Status: COMPLETED ·Phase: PHASE2
-
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
NCT04151667 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
NCT07181941 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
NCT04093596 ·Status: COMPLETED ·Phase: PHASE1
-
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT03601078 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
NCT00675428 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
NCT01421186 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
NCT00742560 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962 ·Status: COMPLETED ·Phase: PHASE1
-
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
NCT04717700 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
NCT00258206 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
NCT04035226 ·Status: COMPLETED